What You'll Want to Know About Nektar Therapeutics' Q2 Results
Nektar Therapeutics (NASDAQ: NKTR) just hasn't seemed to catch a break in 2019 so far. The U.S. Food and Drug Administration (FDA) delayed a key meeting for experimental pain drug NKTR-181. Investors also weren't thrilled with Nektar's launch of a new company, Inheris Biopharma, to market NKTR-181.
But Nektar had an opportunity to get that much-needed break when it announced second-quarter earnings results after the market closed on Thursday. Here's what you need to know about the biotech's latest quarterly update.
Image Source: Getty Images.
Source Fool.com
